Table 4.
PSA (ng/ml) | Upstaging on late imaging | Downstaging on late imaging | Up- and downstaging on late imaging | Lesion only visible on early imaging | No differences |
---|---|---|---|---|---|
< 0.2 | 3 (6.7%) | 2 (4.4%) | 0 | 0 | 40 (88.9%) |
0.2–0.5 | 23 (15.5%) | 10 (6.8%) | 2 (1.4%) | 3 (2.0%) | 110 (74.3%) |
0.5–1 | 7 (17.1%) | 1 (2.4%) | 0 | 1 (2.4%) | 32 (78.0%) |
> 1 | 13 (20.6%) | 1 (1.6%) | 1 (1.6%) | 0 | 48 (76.2%) |
All | 46 (15.5%) | 14 (4.7%) | 3 (1.0%) | 4 (1.3%) | 230 (77.4%) |
Values in parentheses are percentages of row totals
PSA prostate-specific antigen value at the time of PET/CT